Although these drugs were developed primarily to target the EML4-ALK fusion in NSCLC patients with crizotinib resistance, studies in ALK-driven NB cell lines and mouse models have demonstrated their superior potency over crizotinib. The gene discussed is ALK; the disease is neuroblastoma.